

AD \_\_\_\_\_

Award Number: W81XWH-~~6~~ ~~FF~~ ~~I~~ G

TITLE: Ô[ ••cæ\ Á^ç ^^} Å^] ç Ä^&^] ç | Áç å ÅÖÖÜ/ Å ÁÓ^æ öÖæ &^| ÅÖÁ[ c^} çÄ  
T^åãç | Å -Ö@{ | |^•ã ç &^

PRINCIPAL INVESTIGATOR: Ö: ÄÜãåP æÖæ

CONTRACTING ORGANIZATION: Ö[ | |^ Å\ ç^| •ã  
Ççç çÄÖÖÜ/ Å -Ö@{ | |^•ã ç &^

REPORT DATE: Ç | ÅÖFF

TYPE OF REPORT: Åç ç

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE (DD-MM-YYYY) 01-04-2011		2. REPORT TYPE Final		3. DATES COVERED (From - To) 20 MAR 2006 - 19 MAR 2011	
4. TITLE AND SUBTITLE Crosstalk between Leptin Receptor and IGF-IR in Breast Cancer: A Potential Mediator of Chemoresistance				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0452	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Rita Nahta  E-Mail: RNAhta@emory.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Emory University Atlanta, GA 30322				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Obesity is a major risk factor for breast cancer, and is associated with reduced treatment response and reduced overall survival. The obesity-associated hormones IGF-I and leptin and their receptors, IGF-IR and leptin receptor (Ob-R), are elevated in breast cancer. Co-immunoprecipitation and immunoblotting demonstrated that IGF-IR and Ob-R interact in the breast cancer cell lines MDA-MB-231, MCF7, BT474, and SKBR3. Stimulation of cells with IGF-I promoted Ob-R phosphorylation, which was blocked by IGF-IR kinase inhibition. In addition, IGF-I activated downstream signaling molecules in the leptin receptor and IGF-IR pathways. In contrast to IGF-I, leptin did not induce phosphorylation of IGF-IR, indicating that receptor cross signaling is unidirectional, occurring from IGF-IR to Ob-R. Our results demonstrate for the first time a novel interaction and cross talk between the IGF-I and leptin receptors in human breast cancer cells. Our data also showed that inhibition of JAK2, which is immediately downstream of the leptin receptor, reduced proliferation of MCF7 breast cancer cells. Leptin specifically reduced sensitivity to docetaxel, and not to targeted therapies trastuzumab or lapatinib. Further, an unrelated obesity-associated cytokine did not reduce docetaxel sensitivity, suggesting that chemoresistance may be specifically induced by leptin and not by all adipocytokines.					
15. SUBJECT TERMS Breast cancer, leptin, insulin-like growth factor-I, growth factor receptor signaling					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  UU	18. NUMBER OF PAGES  23	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

## Table of Contents


	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	14
Reportable Outcomes.....	14
Conclusion.....	15
References.....	15
Appendices.....	17

## INTRODUCTION

Obesity is an important risk factor associated with the development and progression of breast cancer (1-7), reduced therapeutic efficacy, and higher mortality rates among breast cancer patients (8-11). The obesity-associated hormones insulin-like growth factor-I (IGF-I) and leptin are found at high levels in breast cancer patients (12-15), and their receptors, IGF-IR and Ob-R (leptin receptor is also known as obesity receptor), are overexpressed in a majority of breast cancers (15-17). Increased expression of leptin and Ob-R correlate with increased risk for distant metastasis and reduced overall survival in breast cancer patients (15). Leptin induces proliferation of breast cancer cells via activation of STAT3 (18,19), a transcriptional activator of the anti-apoptotic protein Bcl-2 (20,21). STAT3-dependent overexpression of Bcl-2 was associated with resistance to the chemotherapeutic agent paclitaxel in breast cancer cells (21). In our initial grant proposal, we proposed the following model (**Figure 1**): IGF-IR and leptin receptor interact, inducing phosphorylation of Ob-R, which then activates downstream STAT3 and Bcl-2, resulting in taxane resistance. Our long-term goal was to establish markers of leptin receptor signaling as predictors of taxane response. The ultimate impact would be that these markers of leptin signaling, including serum levels of leptin and IGF-I, and tissue levels of phosphorylated Ob-R, STAT3 and Bcl-2, could be used (1) to identify patients most likely to respond to taxanes, and (2) as therapeutic targets to improve response rates to taxanes in the treatment of breast cancer.


## BODY

**Task 1. Apply nanotechnology-based methods for visualization of IGF-IR and leptin receptor (Ob-R) in real time.** In the first year of this grant, we collaborated with Dr. Konstantin Sokolov at MD Anderson to label nanoparticles with antibodies against IGF-IR or Ob-R. However, nanotechnology was not initially available for this aim when the PI changed




institutions from MD Anderson to Emory University. Thus, this aim has used non-nanotechnology based approaches to assess IGF-IR levels in breast cancer cell lines. We visualized IGF-IR expression in a panel of breast cancer lines by Western blotting, and found a wide variation in levels of phosphorylated and total IGF-IR (**Figure 2**). We used the MCF7 line for most of our work below, as it expressed the highest level of IGF-IR. Additional lines (MDA231 and SKBR3) were used to determine if our data extended to more than one cell line. During the last year of this award, we began collaborating with Dr. Khalid Salaita in the Department of Chemistry at Emory University. Dr. Salaita is an expert on nanoparticle-based approaches to study receptor interactions and signaling. As an initial experiment, Dr. Salaita used our BT474 cell line, which expresses high

levels of IGF-IR and the receptor HER2. He initially used an anti-HER2 antibody to test binding of fluorophore-conjugated antibodies to the membrane of these cells. Streptavidin-biotin labeling of the antibody was performed; cells showed efficient binding of the antibody to the cell surface by fluorescent microscopy. Thus, labeling was successfully achieved in this initial experiment. We are continuing to collaborate with Dr. Salaita's group to label anti-IGF-IR antibody and anti-Ob-R antibody with streptavidin-biotin and expose MCF-7 and BT474 cells to these antibodies in the absence or presence of IGF-I or leptin. This aim was initially delayed due to difficulty in establishing a new collaboration at the PI's institution since the PI changed institutions in 2007. Now that the collaboration has been established, we are able to continue studying receptor-receptor interactions in real time using antibody-labeled nanoparticles.



**Task 2. Demonstrate that IGF-I activates the leptin receptor via IGF-IR crosstalk.**

During the course of this award, aim 2 was completed and published (reference 22, which is attached in the Appendix). The breast cancer cell lines MDA-MB-231 (MDA231), MCF7, BT474, and SKBR3 were examined for IGF-IR and leptin receptor expression and interaction. Cells were lysed for protein and leptin receptor was immunoprecipitated from cells. Immunoblotting demonstrated that IGF-IR was pulled down with the leptin receptor, indicating that they form a complex (**Figure 3A**). Conversely, immunoprecipitation of IGF-IR showed pull down of leptin receptor in all cell lines (**Figure 3B**). Total receptor levels were also examined in the cell lines (**Figure 4**). The leptin receptor has two isoforms. The long isoform is approximately 120 kDa, and possesses kinase activity. The short isoform is 90 kDa and lacks signaling capability, and its function is unclear. All cells showed expression of the long isoform of the leptin receptor, with BT474 cells showing very low levels of the short isoform. IGF-IR expression varied among lines, with MCF7 and BT474 cells showing highest levels. We next wanted to determine the functional consequence of this interaction. MCF7 cells were serum starved overnight to remove hormonal stimulation. Cells were then stimulated with 100ng/mL IGF-I for the indicated time course (**Figure 5A**). Cells were lysed for protein, and immunoblots were performed for total and phosphorylated leptin receptor (using phospho-tyrosine 1141- specific antibody for leptin receptor, Santa Cruz Biotechnology), and for total and phosphorylated IGF-IR (using anti-phospho-tyrosine 1162/1163 insulin receptor/IGF-IR antibody, Biosource). IGF-IR phosphorylation was stimulated within 5 minutes (min).





Importantly, leptin receptor phosphorylation was also stimulated within 5 min, indicating that IGF-IR activation corresponds with activation of leptin receptor, suggesting potential cross talk from IGF-IR to leptin receptor.

Total levels of IGF-IR and leptin receptor isoforms did not change. Downstream of the receptors, the signaling pathways including JAK2, STAT3, ERK1/2, and Akt were examined (**Figure 5B**). The major molecules activated were JAK2 and ERK1/2, and to a lesser extent STAT3 and Akt. We have also confirmed these results in another cell line,

MDA231, in which we also observed phosphorylation of leptin receptor in response to IGF-I stimulation (**Figure 6A**) and activation of JAK2 and ERK1/2 as the major changes in downstream signaling (**Figure 6B**). Hence, the potential biological consequences of IGF-IR cross talk to leptin receptor may be mediated by the JAK2 and MAPK signaling pathways. Cross talk in the opposite direction, from leptin receptor to IGF-IR, was also examined. For this experiment, MCF7 cells were serum starved overnight, and stimulated with 100ng/mL leptin for the indicated time points (**Figure 7**). Immunoblots of total lysates were probed for phospho-leptin receptor and phospho-IGF-IR. Our preliminary results indicated that leptin receptor is phosphorylated as expected, but we did not detect phosphorylated IGF-IR. Next, MCF7

cells were serum-starved overnight, and then treated with 10 $\mu$ M Src kinase inhibitor I (EMD Chemicals, Gibbstown, NJ) overnight, followed by IGF-I (100ng/mL) stimulation for 15 min. Protein lysates were immunoblotted for phosphorylated and total Src, IGF-IR, and Ob-R (**Figure 8**). Inhibition of Src kinase appeared to partially reduce IGF-I-mediated phosphorylation of the IGF-IR and Ob-R, suggesting that Src kinase activity is important to IGF-IR kinase activity and to its cross talk to Ob-R. We also pre-treated MCF7





cells for 1 hour with inhibitors of Src, Jak2, PI3K, or MAPK prior to IGF-I stimulation and examined Ob-R phosphorylation (**Figure 9**). The short-term treatment with inhibitors did not inhibit IGF-IR cross talk to Ob-R, in contrast to the overnight treatment with Src inhibitor I (**Figure 8**). Since insulin receptor shares homology with IGF-IR, we inhibited insulin receptor with 10  $\mu$ M HNMPA (EMD Chemicals) overnight

followed by IGF- I stimulation and immunoblotted for phosphorylated and total IGF-IR and Ob-R (**Figure 10**). IGF-I mediated phosphorylation of Ob-R in the presence of HNMPA, suggesting that IGF-I stimulation of insulin receptor does not mediate the cross talk to Ob-R. However, stimulation with insulin does phosphorylate Ob-R (**Figure 11**), suggesting that insulin may be activating IGF-IR which then cross talks to Ob-R.



**Task 3. Demonstrate that Ob-R signaling activated by leptin or IGF-I contributes to taxane resistance.**

MCF7, BT474, and SKBR3 cells were either untreated, treated with 100ng/mL leptin for 36 hours (h), 5nM docetaxel for 24 h, or treated with a combination

of leptin and docetaxel, where cells were pre-treated with leptin for 12 hours and then docetaxel was added to the media for an additional 24 hours. DNA fragmentation as a measure of apoptosis was examined using the Cell Death ELISA Plus Kit (Roche Applied Science) per manufacturer instructions. With this particular experimental design, very little change in DNA fragmentation was observed in MCF7 and BT474 cells (**Figure 12**). In SKBR3 cells docetaxel alone caused a 2-fold increase in DNA fragmentation, and the added contribution of leptin was negligible. We then treated MCF7 cells with IGF-I and docetaxel, and examined cytotoxicity



using a clonogenic assay. MCF7 cells were treated with 100ng/mL IGF-I +/- 10nM docetaxel for 1 week, with media plus IGF-I or drug changed daily. Photographs of cultures were taken to assess colony growth (**Figure 13**). IGF-I partially reduced docetaxel sensitivity, as a higher colony count was observed in the IGF-I + docetaxel cultures. Dose-response profiles were established for MCF7 and MDA231 cells treated with paclitaxel (**Figure 14**). The cell lines responded similarly to paclitaxel, with both lines showing 50% inhibition of proliferation (IC<sub>50</sub>) at approximately 10-20 nM. In our initial DoD application, we hypothesized that obesity-associated hormones will reduce taxane sensitivity. Thus, we treated MCF7 cells with DMSO control or 10 nM docetaxel while being maintained in regular cell culture DMEM media containing 10% fetal calf serum, conditioned media (CM) from 3T3 mouse adipocytes, or CM from human abdominal omental adipocytes. MTS proliferation assays were performed after 6 days (**Figure 15**); all treatments were done in 6 replicates. Our results indicated that 3T3 CM reduced response to docetaxel, but that omental CM did not change response. In addition, we hypothesized in the initial application that inhibition of Ob-R and IGF-IR signaling will increase taxane sensitivity. We were unable to identify effective siRNA or shRNA against Ob-R. Thus, we used pharmacologic inhibition of downstream









JAK/STAT signaling to determine if inhibition of Ob-R signaling affects taxane response. HCC1806, MDA231, and MDA468 breast cancer cells were treated with 2-fold serial dilutions of WP1066, a JAK2/STAT3 inhibitor, and proliferation was measured after 6 days (**Figure 16**). All cells showed similar response with IC<sub>50</sub> approaching 8 $\mu$ M. We treated MCF7 with the IGF-IR inhibitor PPP plus JAK2 inhibitor (**Figure 17**), and have not observed any additive or synergistic effects. Interestingly, despite having high endogenous levels of IGF-IR, MCF7



cell proliferation is unaffected by IGF-IR inhibition alone. In contrast, cells appear to be partially dependent upon JAK2 signaling, as JAK2 inhibition produced a dose-dependent decline in cell proliferation. The IC<sub>50</sub> of JAK2 inhibitor in MCF7 cells was consistent with the IC<sub>50</sub>s observed in response to WP1066 in HCC1806, MDA231, and MDA468. Finally, since we have not found an effective

siRNA against leptin receptor, we tested a mutant recombinant human leptin peptide. Mutant leptin did not increase inhibition of MCF7 cell proliferation achieved by the IGF-IR inhibitor PPP (**Figure 18**). These results are consistent with data shown in Figure 17, indicating that PPP does not increase the effect of JAK2 inhibition on MCF7 cell proliferation. Interestingly, in Figure 18, PPP alone reduced proliferation, in contrast to Figure 17. Thus, combined IGF-IR and Ob-R/JAK2 inhibition may not be beneficial, but rather JAK2 inhibition or IGF-IR inhibition alone may inhibit proliferation of breast cancer cells. In




our initial DoD application, we hypothesized that the obesity-associated hormones leptin and IGF-I will reduce taxane sensitivity. MDA231 ER-negative breast cancer cells and MCF7 ER-positive breast cancer cells were pre-treated for 24 h with 100ng/mL leptin or solvent control, and then treated with a combination of leptin 100ng/mL (or control) plus two-fold serial dilutions of docetaxel ranging from 0nM to 100nM. After 6 days, proliferation was measured using the MTS colorimetric assay (Promega). Co-treatment with leptin reduced response to docetaxel in MDA231 and MCF7 cells (**Figure 19**), with statistically significant results observed at the middle doses of docetaxel. The values shown in the graph reflect average fold proliferation relative to control cells treated with DMSO +/- leptin. Error bars represent the standard deviation between 6

replicates per group. Thus, increased exogenous exposure to leptin, which may occur during obesity, may result in reduced response to the chemotherapeutic drug docetaxel in breast cancer. In contrast, co-treatment of HER2-overexpressing breast cancer cells with leptin plus either the HER2-targeted therapy trastuzumab or lapatinib resulted in reduced response to HER2-targeted therapies, but results did not reach statistical significance. For this experiment, SKBR3 HER2-overexpressing breast cancer cells were treated with 1000 ng/mL leptin for 24 h, and then with either 10  $\mu$ g/mL trastuzumab or 0.1  $\mu$ M lapatinib for an additional 72 h. Cells were trypsinized, stained with trypan blue, and counted under a microscope. The percentage of viable cells is shown relative to untreated cells (**Figure 20**). Error bars represent standard deviation between duplicate cultures. These results indicate that the antagonistic effects of leptin on drug response may be specific for docetaxel, as significant effects were not observed with trastuzumab or lapatinib. As another comparison, we tested the effects of another adipocyte-secreted factor called GDF15 on response to docetaxel. HCC1806 ER-negative breast cancer cells were treated with 1nM, 10nM, or 100nM docetaxel in the absence or presence of




of viable cells is shown relative to untreated cells (**Figure 20**). Error bars represent standard deviation between duplicate cultures. These results indicate that the antagonistic effects of leptin on drug response may be specific for docetaxel, as significant effects were not observed with trastuzumab or lapatinib. As another comparison, we tested the effects of another adipocyte-secreted factor called GDF15 on response to docetaxel. HCC1806 ER-negative breast cancer cells were treated with 1nM, 10nM, or 100nM docetaxel in the absence or presence of


100ng/mL recombinant human GDF15. After 6 days, proliferation was measured using the MTS colorimetric assay (Promega). A dose of 10nM docetaxel resulted in 50% inhibition of proliferation, which was not altered by co-treatment with GDF15 (**Figure 21**). Thus, whereas leptin reduced response to docetaxel, another obesity-associated cytokine did not show similar effects on docetaxel sensitivity.




**Figure 14. Dose-response to paclitaxel.** MCF7 and MDA231 cells were treated with 2-fold serial dilutions of paclitaxel ranging from 5nM to 160nM for 6 days in 6 replicates per drug concentration. MTS assays were then performed and % proliferation is shown relative to control. Control reflects cells treated with the paclitaxel solvent DMSO at amount present in the highest concentration of paclitaxel (160 nM).




**Figure 15. Response of MCF7 cells to docetaxel in adipocyte conditioned media.** MCF7 cells were plated in DMEM + 10% FCS (regular complete media), conditioned media (CM) from mouse 3T3 adipocytes, or CM from human abdominal omental cells (Om). Cells were untreated or treated for 6 days in 6 replicates per group with 10 nM docetaxel. MTS assays were performed and % proliferation is shown relative to DMSO control.




**Figure 16. Dose-response to JAK2/STAT3 inhibitor WP1066.** HCC1806, MDA231, and MDA468 cells were treated with 2-fold serial dilutions of WP1066 ranging from 1uM to 8uM for 6 days in 6 replicates per drug concentration. MTS assays were then performed and % proliferation is shown relative to DMSO control.





**Figure 17. Effect of combined inhibition of IGF-IR and JAK2 on MCF7 cell proliferation.** MCF7 cells were treated for 6 days in 6 replicates per group with DMSO (C), IGF-IR inhibitor PPP ranging from 250nM to 1000nM, JAK2 inhibitor ranging from 5uM to 20uM, or a combination of the two inhibitors. MTS assays were performed and % proliferation is shown relative to DMSO control.



**Figure 18. Leptin mutant did not inhibit MCF7 cell proliferation.** MCF7 cells were treated for 6 days in 6 replicates per group with DMSO (C), 250 nM IGF-IR inhibitor PPP (P), 2.5 ug/mL recombinant human leptin mutant (L), or a combination of P+L. MTS assays were performed and % proliferation is shown relative to DMSO control.



**Figure 19. Leptin reduces response to docetaxel in breast cancer cells.**



## KEY RESEARCH ACCOMPLISHMENTS

Key accomplishments during the entire funding period of this project were:

- (1) Discovery that IGF-IR and leptin receptor interact [published in ref. 22]
- (2) Discovery that IGF-I induces leptin receptor phosphorylation [published in ref. 22]
- (3) Discovery that IGF-IR kinase inhibition blocks signaling to leptin receptor [published in ref. 22]
- (4) Discovery that IGF-IR cross talk to Ob-R is unidirectional [published in ref. 22]
- (5) Potential role of Src kinase as mediator of IGF-IR cross talk to Ob-R
- (6) Finding that insulin stimulates phosphorylation of Ob-R
- (7) Demonstration that IGF-I reduces toxicity of docetaxel in breast cancer cell cultures
- (8) Paclitaxel dose-response curves were established for a panel of breast cancer cell lines.
- (9) Finding that adipocyte conditioned media reduces docetaxel dose-response, demonstrating that adipocytes may reduce response to docetaxel.
- (10) JAK2 inhibition produced a dose-dependent decline in MCF7 cell proliferation.
- (11) Studies suggested that combined inhibition of IGF-IR and JAK2 were not beneficial, but that single agent inhibition of IGF-IR or JAK2 may be effective.
- (12) Data suggested that leptin specifically reduces sensitivity to docetaxel, and not to targeted therapies trastuzumab or lapatinib. Further, an unrelated obesity-associated cytokine did not reduce docetaxel sensitivity, suggesting that chemoresistance may be specifically induced by leptin and not all adipocytokines.

## REPORTABLE OUTCOMES

Receipt of this DoD Award as an indication of expertise in the area of breast cancer endocrinology and drug resistance has contributed to several opportunities for the PI.

- (1) The research findings were published. The citation (listed as *in press* in first annual report, and has since been published) is as follows: Ozbay T, Nahta R. (2008) A novel unidirectional cross talk from the insulin-like growth factor-I receptor to the leptin receptor in human breast cancer cells. *Mol Cancer Res* 6: 1052-1058.
- (2) The PI has been invited to serve on several grant review study sections: Department of Defense / CDMRP Breast Cancer Research Program (BCRP) Concept, IDEA, and Post-doc review panels, 2008-2010; 2010 New Zealand Breast Cancer CURE Research Trust grant reviewer; 2011 The Mary Kay Foundation Research Review Committee
- (3) The project funded by this IDEA Award was chosen as for an oral symposium at the DoD BCRP 2008 Era of Hope meeting. The PI presented the results of this grant in the “Modifiable risk factors” session of that meeting.
- (4) The PI has become an Editorial Board Member for several scientific journals (*International Scholarly Research Network (ISRN) Oncology*, *Current Pharmacogenomics and Personalized Medicine*, *Medical Hypotheses*, *Breast Cancer: Basic and Clinical Research*, and Guest Editor for *International Journal of Breast Cancer*).
- (5) In addition, start-up funding has been received from Georgia Cancer Coalition Distinguished Scholars Program, and grant funding was received from The Mary Kay Foundation for a project unrelated to this IDEA Award. The honor of receiving the IDEA Award and the established funding record of the PI may have positively influenced selection of the PI for receipt of these other awards.
- (6) In addition, because of her recognized expertise in the area of breast cancer drug resistance, the PI was invited to speak at the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Research Program Investigators Meeting on 10/09/2010 in Las Vegas, where she spoke about Mechanisms of Herceptin resistance.

## CONCLUSION

As published in reference 22, we made the following discoveries. (1) The IGF-I and leptin receptors interact in human breast cancer cells. (2) Cross signaling occurs from IGF-IR to Ob-R in breast cancer. IGF-I stimulation induces phosphorylation and activation of Ob-R, while IGF-IR kinase inhibition blocks IGF-I-mediated Ob-R activation. Downstream signaling molecules JAK2, STAT3, Akt, and ERK1/2, all of which are functional in the leptin and IGF-IR pathways as well as in multiple other signaling pathways, were activated by IGF-I stimulation. (3) Cross talk is unidirectional, as leptin does not activate IGF-IR. Thus, leptin is not likely to affect IGF-IR oncogenic function in breast cancer. However, since IGF-IR cross talks to Ob-R, it is feasible that Ob-R may contribute to IGF-IR molecular or biological effects, and is worthy of further study. Thus, we have identified a novel receptor interaction and unidirectional cross talk involving the IGF-IR and leptin receptor. As discussed in a previous annual report, we have also shown the following. (4) Insulin appears to stimulate Ob-R phosphorylation as well, although inhibition of insulin receptor does not block IGF-I-mediated Ob-R phosphorylation. Insulin is known to bind and activate IGF-IR; thus, insulin may be activating Ob-R via IGF-IR. (5) Adipocyte-secreted factors found in conditioned media collected from adipocytes reduced response to taxanes. Furthermore, MCF7 cells appeared to be dependent upon JAK2 signaling, which is downstream of leptin receptor and potentially upregulated during obesity. Thus, JAK2 inhibition downstream of leptin receptor may be a potential strategy for combating obesity-associated breast cancer and possibly for improving chemosensitivity of obesity-associated breast cancers. As discussed in this report, the following additional conclusions are made. (6) Leptin and not another adipocytokine (GDF15) appeared to specifically reduce response to docetaxel, with no effects on sensitivity to HER2-targeted therapies. Thus, leptin appears to play a potential role in mediating taxane resistance in breast cancer.

**All final reports must include a bibliography of all publications and meeting abstracts and a list of personnel (not salaries) receiving pay from the research effort.**

### Publications:

Ozbay T, Nahta R. (2008) A novel unidirectional cross talk from the insulin-like growth factor-I receptor to the leptin receptor in human breast cancer cells. *Mol Cancer Res* 6: 1052-1058.

### Meeting Abstract:

June 2008, Invited speaker, Department of Defense Breast Cancer Research Program Era of Hope Meeting, Baltimore, MD, oral presentation: "A novel unidirectional cross talk from the insulin-like growth factor-I receptor to the leptin receptor in human breast cancer cells"

### List of Personnel:

Rita Nahta, Ph.D., PI of grant  
Jayashree Joshi, Post-doc

## REFERENCES

1. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A. (2002) Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). *Cancer Causes Control* 13: 741-751.
2. Sweeney C, Blair CK, Anderson KE, Lazovich D, Folsom AR. (2004) Risk factors for breast cancer in elderly women. *Am J Epidemiol* 160: 868-875.
3. Maehle BO, Tretli S, Thorsen T. (2004) The associations of obesity, lymph node status and prognosis in breast cancer patients: dependence on estrogen and progesterone receptor status. *APMIS* 112: 349-357.
4. Chlebowski RT. (2005) Obesity and early-stage breast cancer. *J Clin Oncol* 23: 1345-1347.
5. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. (1990) Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. *J Clin Oncol* 8: 1327-1334.
6. Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R. (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. *J Clin Oncol* 23: 774-782.

7. Kroenke CH, Chen WY, Rosner B, Holmes MD. (2005) Weight, weight gain, and survival after breast cancer diagnosis. *J Clin Oncol* 23: 1370-1378.
8. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ. (1990) Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. *Cancer* 65: 200-206.
9. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. (1994) Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. *Ann Intern Med* 120: 18-25.
10. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thurlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A; International Breast Cancer Study Group. (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 15: 875-884.
11. Enger SM, Greif JM, Polikoff J, Press M. (2004) Body weight correlates with mortality in early-stage breast cancer. *Arch Surg* 139: 954-958; discussion 958-960.
12. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 14: 699-704.
13. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. *Lancet* 351: 1393-1396.
14. Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C, Mussa A. (2000) Leptin expression in colorectal and breast cancer patients. *Int J Mol Med* 5: 421-426.
15. Ishikawa M, Kitayama J, Nagawa H. (2004) Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. *Clin Cancer Res* 10: 4325-4331.
16. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N. (1990) Insulin-like growth factor receptor expression and function in human breast cancer. *Cancer Res* 50: 48-53.
17. Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL. (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. *Cancer Res* 58:1159-1164.
18. Banks AS, Davis SM, Bates SH, Myers MG Jr. (2000) Activation of downstream signals by the long form of the leptin receptor. *J Biol Chem* 275:14563-14572.
19. Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, Wu H, Wu G, Wang X, Shang Y. (2004) Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. *Cancer Res* 64: 5870-5875.
20. Stephanou A, Brar BK, Knight RA, Latchman DS. (2000) Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. *Cell Death Differ* 7: 329-330.
21. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. *Oncogene* 21: 7611-7618.
22. Ozbay T, Nahta R. (2008) A novel unidirectional cross talk from the insulin-like growth factor-I receptor to the leptin receptor in human breast cancer cells. *Mol Cancer Res* 6: 1052-1058.

## APPENDICES

Reference [22] was a direct result of this Award and is attached.

## SUPPORTING DATA

N/A



---

# A Novel Unidirectional Cross-Talk from the Insulin-Like Growth Factor-I Receptor to Leptin Receptor in Human Breast Cancer Cells

Tuba Ozbay<sup>1,3</sup> and Rita Nahta<sup>1,2,3,4</sup>

Departments of <sup>1</sup>Pharmacology and <sup>2</sup>Hematology/Oncology, School of Medicine, <sup>3</sup>Winship Cancer Institute, and <sup>4</sup>Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, Georgia

## Abstract

**Obesity is a major risk factor for the development and progression of breast cancer. Increased circulating levels of the obesity-associated hormones leptin and insulin-like growth factor-I (IGF-I) and overexpression of the leptin receptor (Ob-R) and IGF-I receptor (IGF-IR) have been detected in a majority of breast cancer cases and during obesity. Due to correlations between increased leptin, Ob-R, IGF-I, and IGF-IR in breast cancer, we hypothesized that molecular interactions may exist between these two signaling pathways. Coimmunoprecipitation and immunoblotting showed that IGF-IR and Ob-R interact in the breast cancer cell lines MDA-MB-231, MCF7, BT474, and SKBR3. Stimulation of cells with IGF-I promoted Ob-R phosphorylation, which was blocked by IGF-IR kinase inhibition. In addition, IGF-I activated downstream signaling molecules in the leptin receptor and IGF-IR pathways. In contrast to IGF-I, leptin did not induce phosphorylation of IGF-IR, indicating that receptor cross-signaling is unidirectional, occurring from IGF-IR to Ob-R. Our results show, for the first time, a novel interaction and cross-talk between the IGF-I and leptin receptors in human breast cancer cells. (Mol Cancer Res 2008;6(6):1052–8)**

## Background

Obesity is an important and manageable risk factor for the development and progression of postmenopausal breast cancer (1). Increased body weight and body mass index are associated with reduced disease-free and overall survival and poorer therapeutic response rates in breast cancer patients, regardless of menopausal status or age (2). Although the exact molecular mechanisms by which obesity influences cancer biology are

unknown, there is evidence suggesting that increased production and secretion of adipocyte-derived growth factors and hormones contributes to cellular transformation and tumorigenesis (3, 4). The obesity-associated hormones leptin and insulin-like growth factor-I (IGF-I) have been independently implicated in the connection between obesity and breast cancer (5).

Leptin, a product of the obese (*ob*) gene, is an adipocytokine that regulates appetite, bone formation, reproduction, cellular proliferation, and angiogenesis (6). Because of the strong association between human obesity and elevated levels of circulating leptin, this hormone has been widely studied in the fields of nutrition and weight management (7). More recently, however, leptin has emerged as a potential factor contributing to mammary tumorigenesis. *In vitro* studies showed that leptin stimulates the growth, survival, and transformation of breast cancer cells (5), primarily by activating the Janus-activated kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway (8, 9) and the phosphoinositol-3-kinase/Akt and mitogen-activated protein kinase (MAPK) pathways (10). Leptin induces cell cycle progression by up-regulating cyclin D1 expression and cyclin-dependent kinase 2 activity, as well as by inactivating the retinoblastoma growth suppressing protein (11). Importantly, leptin and its receptor (Ob-R) were found to be overexpressed in a majority of breast cancer tissues, especially in high-grade tumors, but absent or expressed at very low levels in normal mammary epithelium or benign tumors (5, 12). In addition, leptin-deficient mice have a decreased incidence of spontaneous and oncogene-induced mammary tumors (13). Thus, leptin signaling seems to play an important role in breast cancer biology.

Similar to leptin, increased levels of IGF-I and its receptor are detected in sera and primary tumors of breast cancer patients (14, 15), and transgenic overexpression of IGF-I receptor (IGF-IR) has been shown to induce mammary tumor formation (16). IGF-I is an important endocrine, paracrine, and autocrine regulator of breast epithelial cell growth. Increased signaling through the IGF-IR results in increased cellular proliferation, mitogenesis, and survival and decreased apoptosis, causing resistance to numerous antineoplastic agents (14, 17). For these reasons, the IGF-IR has become an important therapeutic target for drug discovery in breast oncology (17).

Cross-talk between different growth factor receptor families is frequently observed in tumors. This mechanism allows cancer cells to enhance downstream signaling resulting in greatly increased proliferation, mitogenesis, and cell survival.

---

Received 10/30/07; revised 3/6/08; accepted 3/6/08.

**Grant support:** Department of Defense grant W81XWH0610452 IDEA (R. Nahta), National Cancer Institute grant K01CA118174 (R. Nahta), and Georgia Cancer Coalition Distinguished Cancer Scholar award (R. Nahta).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Rita Nahta, Department of Pharmacology, Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322. Phone: 404-778-3097; Fax: 404-778-5530. E-mail: RNAHTA@EMORY.EDU

Copyright © 2008 American Association for Cancer Research.

doi:10.1158/1541-7786.MCR-07-2126

The IGF-IR has been shown to interact and cross-talk with multiple receptors, including the epidermal growth factor receptor (EGFR; ref. 18), HER2 (19), platelet-derived growth factor receptor (20), and the estrogen receptor (14). Due to the correlations between elevated levels of leptin, IGF-I, and their associated receptors with obesity and breast cancer, we hypothesized that interactions and/or cross-talk may occur between these two signaling pathways.

## Results

### *IGF-IR and Leptin Receptor Interact in Human Breast Cancer Cells*

The human breast cancer lines MDA-MB-231 (MDA231), MCF7, BT474, and SKBR3 were examined for expression of the IGF-IR and leptin receptor (Ob-R). Immunoblotting of total protein lysates (Fig. 1A) showed that the two major isoforms of Ob-R, called Ob-Rb (longer isoform) and Ob-Rt (shorter isoform), are expressed at similar levels in all cell lines (Fig. 1B). IGF-IR is expressed at higher levels in MCF7 and BT474 cells versus SKBR3 and MDA231 cells, with highest levels observed in MCF7 cells (Fig. 1B).


Immunoprecipitation of Ob-R with subsequent immunoblotting for IGF-IR showed that Ob-Rb and Ob-Rt are both pulled down with IGF-IR in all four cell lines (Fig. 2A). Conversely, IGF-IR immunoprecipitation pulled down Ob-Rb and Ob-Rt in each cell line, with preferential interaction observed with the shorter isoform of Ob-R in MCF7, BT474, and SKBR3 cells (Fig. 2B). Quantitation showed that IGF-IR was pulled down with Ob-R to a similar extent in all four lines (Fig. 2C). Total Ob-R was pulled down with IGF-IR in all four lines; however, higher levels of Ob-R interacting with IGF-IR was observed in MCF7 cells (Fig. 2C), likely due to the higher expression level of total IGF-IR in these cells (Fig. 1B). Negative controls in which cell lysates were immunoprecipitated with rabbit IgG confirmed that IGF-IR and Ob-R were not pulled down (Fig. 2D). In addition, because IGF-IR has been shown to interact with insulin receptor (21), we blotted IGF-IR immunoprecipitates for insulin receptor as a positive control (Fig. 2D). Insulin receptor was pulled down with IGF-IR in all four lines. Finally, another tyrosine kinase receptor, EGFR, was immunoprecipitated and blotted for IGF-IR in all lines (Fig. 2D). Collectively, the results of these immunoprecipitation experiments indicate that the IGF-IR and leptin receptor interact in human breast cancer cells.

### *IGF-IR Cross-Signals to the Leptin Receptor*


To determine the effect of IGF-IR/leptin receptor interaction on receptor signaling, MCF7 cells were serum-starved overnight and then stimulated with IGF-I (100 ng/mL) for up to 1 hour. IGF-IR phosphorylation was induced within 5 minutes (Fig. 3A), while total IGF-IR levels were unaltered. Importantly, phosphorylation of Ob-R was also induced within 5 minutes of IGF-I exposure, suggesting potential cross-signaling from IGF-IR to leptin receptor. Similarly, in BT474 cells (Fig. 3B) and MDA231 cells (Fig. 3C), IGF-I stimulation induced phosphorylation of both IGF-IR and Ob-R within 5 minutes, without affecting total levels of either receptor. To determine if IGF-I stimulates phosphorylation of the leptin

receptor via the IGF-IR kinase, MCF7 cells were treated with the IGF-IR kinase inhibitor I-OMe-AG538 and stimulated with IGF-I (Fig. 3D). Immunoblotting showed that inhibition of IGF-IR kinase blocked IGF-I-stimulated phosphorylation of leptin receptor. Thus, IGF-I cross-signals to the leptin receptor via the IGF-IR kinase.

Having established that IGF-IR stimulates phosphorylation of the leptin receptor, we examined IGF-I-mediated effects on downstream receptor signaling. MCF7 cells were stimulated with IGF-I and immunoblotted for phosphorylated and total JAK2 and STAT3 (Fig. 4A) and for phosphorylated and total Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and p38 MAPK (Fig. 4B). Significant phosphorylation of JAK2 and STAT3 was observed in response to IGF-I within 5 minutes. IGF-I also activated the phosphoinositide-3-kinase pathway, as shown by phosphorylation of Akt. Phosphorylation of ERK1/2 and p38 MAPK was rapidly activated by



**FIGURE 1.** Expression of IGF-IR and Ob-R in breast cancer lines. The breast cancer lines MDA-MB-231 (MDA231), MCF7, BT474, and SKBR3 were lysed for total protein. **A.** Total protein lysates were immunoblotted for Ob-R using the H-300 polyclonal antibody, which recognizes both the long Ob-Rb isoform and the shorter Ob-Rt isoform of the leptin receptor. Immunoblotting was also done for total IGF-IR and for actin as a loading control. **B.** Bands on immunoblots were quantitated using NIH ImageJ and are expressed relative to expression levels in MDA231 cells (lane 1). Error bars, SD between three independent experiments. Total Ob-R levels were similar among the four lines; IGF-IR was expressed at the highest level in MCF7 cells, with BT474 cells showing moderate expression compared with the other two lines which expressed the lowest levels of IGF-IR.



**FIGURE 2.** Interaction between IGF-IR and Ob-R in breast cancer. The breast cancer lines MDA-MB-231 (MDA231), MCF7, BT474, and SKBR3 were lysed for total protein. Ob-R (**A**) and IGF-IR (**B**) were immunoprecipitated (*IP*; 1  $\mu$ g of antibody) from total protein extracts (200  $\mu$ g) and immunoblotted (*IB*) to detect IGF-IR and Ob-R. Ob-R immunoprecipitation pulled down IGF-IR; conversely, IGF-IR immunoprecipitation pulled down Ob-R. **C.** Quantitation of immunoprecipitated experiments. Error bars, SD between three independent experiments. Values were normalized to the MDA231 cells (*lane 1*). **D.** Cell lysates were immunoprecipitated using 1  $\mu$ g rabbit IgG and immunoblotted for IGF-IR and Ob-R as a negative control. On IGF-IR blot, total lysate from MCF7 cells is included as a positive control (+) for the antibody; on Ob-R blot, lysate from COLO320DM cells was purchased as a positive control (+) for the H-300 antibody from Santa Cruz. As a positive immunoprecipitated control, cell lysates were immunoprecipitated with IGF-IR antibody and blotted for insulin receptor, which is known to interact with IGF-IR. EGFR tyrosine kinase receptor was also immunoprecipitated and blotted for Ob-R, with MDA231 total cell lysate added as a positive control for EGFR. Our results show that the IGF-IR and leptin receptor form a protein complex in breast cancer cells.

transient versus other signaling pathways. Collectively, these results support the concept that IGF-I cross-activates the leptin receptor signaling pathway, although the signaling molecules examined are downstream of multiple growth factor receptors and, thus, do not strictly confirm activation of leptin receptor signaling. However, as leptin receptor phosphorylation was induced by IGF-I and blocked by IGF-IR kinase inhibitor on Tyr<sup>1141</sup>, which is the phosphorylation site that binds STAT3 and activates downstream signaling, our results strongly suggest that IGF-IR induces activation of the leptin receptor.

#### IGF-IR/Leptin Receptor Cross-Talk Is Unidirectional

We next examined whether cross-talk occurs in the opposite direction, i.e., from the leptin receptor to IGF-IR. MCF7 cells


were serum starved and stimulated with leptin (1,000 ng/mL) for up to 6 hours. Leptin induced phosphorylation of leptin receptor within 5 minutes (Fig. 5A). However, phosphorylation of IGF-IR at either Tyr<sup>1131</sup> or Tyr<sup>1135/1136</sup> was not stimulated by leptin at these time points of up to 6 hours nor was it stimulated at shorter time point increments or longer time points of up to 24 hours or with lower doses of leptin (not shown). As a positive control, IGF-I stimulated phosphorylation of IGF-IR as expected and also induced phosphorylation of leptin receptor as previously observed (Fig. 3). Similarly, BT474 cells stimulated with leptin showed phosphorylation of leptin receptor but not of IGF-IR at either of the three sites examined (Tyr<sup>1131</sup>, Tyr<sup>1135</sup>, and Tyr<sup>1136</sup>; Fig. 5B). Thus, our results suggest a unidirectional cross-talk from the IGF-IR to the leptin receptor in breast cancer cells.

## Discussion


Epidemiologic studies estimate that obesity increases the risk of breast cancer by up to 50% (3). The molecular mechanisms guiding obesity-associated breast cancer are not well understood, but are likely to involve an increased production and secretion of obesity-associated hormones (22). IGF-I and leptin are capable of regulating mammary tissue growth at multiple levels (5). Both hormones are secreted by abdominal adipocytes, resulting in endocrine effects on various tissues, including the breast. Paracrine growth stimulatory effects occur via IGF-I and leptin released by the adipocyte component of stroma surrounding breast epithelial cells or existing breast tumor cells. In addition, an autocrine signaling component is present as breast cancer cells themselves produce and secrete IGF-I and leptin and express cell surface receptors for both ligands. Thus, IGF-I and leptin represent a molecular link between adipose tissue and mammary tissue.

The IGF-IR and Ob-R signaling pathways have each been independently implicated in the development and progression

of breast cancer. High circulating levels of IGF-I have been associated with an increased risk of developing breast cancer, and patients with existing breast cancer expressed high serum levels of IGF-I (17). In addition, transgenic mouse models overexpressing IGF-I, IGF-II, or IGF-IR showed an increased incidence of mammary tumor formation (16, 17, 23, 24). Conversely, liver-specific depletion of IGF-I caused reduced circulating levels of IGF-I in mice, resulting in diminished IGF-I endocrine effects on mammary tissue and, ultimately, reduced incidence of breast tumors (25). Similar to the IGF-I signaling pathway, leptin signaling has been associated with breast cancer. Leptin and its receptor were shown by immunohistochemistry to be overexpressed in primary and metastatic breast cancers relative to noncancer tissues (5). Expression of both leptin and Ob-R was most abundant among high-grade tumors, supporting a role for this pathway in breast cancer progression. In addition, *in vivo* models showed that whereas mice that overexpress transforming growth factor- $\alpha$  developed mammary tumors, leptin-deficient transforming growth factor- $\alpha$



**FIGURE 3.** Evidence of cross-talk from IGF-IR to Ob-R. IGF-I induces phosphorylation of Ob-R, which is blocked by IGF-IR kinase inhibition. MCF7 (**A**), BT474 (**B**), and MDA231 (**C**) cells were serum-starved overnight and then stimulated with IGF-I (100 ng/mL) for 1, 5, 15, 30, or 60 min. Cells were lysed for protein, and total protein extracts (50  $\mu$ g) were immunoblotted (SS, serum-starved control) for p-Y<sup>1141</sup>-Ob-R (phosphorylated Tyr<sup>1141</sup> on leptin receptor), total Ob-R, p-Tyr<sup>1131</sup> IGF-IR (phosphorylated Tyr<sup>1131</sup> on IGF-IR), IGF-IR  $\beta$ , and actin as a loading control. IGF-I stimulated phosphorylation of IGF-IR within 5 min in all cell lines. Importantly, phosphorylation of the leptin receptor was also induced within 5 min of IGF-I exposure. Total receptor levels did not change. **D.** MCF7 cells were serum-starved overnight, then stimulated with IGF-I (100 ng/mL) for 5 min, and/or treated with the IGF-IR kinase inhibitor I-OMe-AG538 (10  $\mu$ mol/L overnight). Total protein was immunoblotted for p-Y<sup>1141</sup>-Ob-R, total Ob-R, p-Tyr<sup>1131</sup> IGF-IR, and total IGF-IR. Experiments were done at least twice. Inhibition of IGF-IR kinase blocked IGF-I-mediated phosphorylation of leptin receptor, supporting cross-talk from the IGF-IR kinase to leptin receptor. SS, serum-starved control; I, IGF-I; AG, I-OMe-AG538; I + AG, IGF-I + I-OMe-AG538.



**FIGURE 4.** IGF-I activates downstream signaling. MCF7 cells were serum-starved overnight and then stimulated with IGF-I (100 ng/mL) for 1, 5, 15, 30, or 60 min. Total protein extracts (50  $\mu$ g) were immunoblotted for the downstream leptin signaling molecules p-STAT3 (Tyr<sup>705</sup>), total STAT3, p-JAK2 (Tyr<sup>221</sup>), and total JAK2 (24<sup>B11</sup>) (**A**) and for molecules downstream of both leptin receptor and IGF-IR, p-Akt (Ser<sup>473</sup>), total Akt, p-p42/p44 MAPK (Thr<sup>202</sup>/Tyr<sup>204</sup>, ERK1/2), total p42/p44 MAPK (ERK1/2), p-p38 MAPK (pThr<sup>180</sup>/Tyr<sup>182</sup>), and total p38 MAPK (**B**). IGF-I induced phosphorylation of STAT3 and JAK2, consistent with IGF-I-mediated activation of leptin signaling, and also activated Akt, ERK1/2, and p38 MAPK signaling. Since the same lysates were used in **A** and **B**, the same actin blot is shown.

mice were resistant to mammary tumor development (13), illustrating the important contribution of the leptin signaling pathway to some forms of breast cancer. Hence, because IGF-I and leptin are frequently detected in the serum of breast cancer patients and both receptors are overexpressed in a majority of breast tumors, we sought to determine whether molecular interactions occur between IGF-IR and leptin receptor in breast cancer.

We showed the following novel findings (Fig. 6):

(a) The IGF-I and leptin receptors interact in human breast cancer cells. Of potential interest, IGF-IR may preferably associate with Ob-Rt versus Ob-Rb in MCF7, BT474, and SKBR3 cells, as more of this isoform was pulled down in the

IGF-IR immunoprecipitates (Fig. 2B); total levels of both Ob-R isoforms were similar in each line (Fig. 1A).


(b) Cross-signaling occurs from IGF-IR to Ob-R in breast cancer. IGF-I stimulation induces phosphorylation and activation of Ob-R, whereas IGF-IR kinase inhibition blocks IGF-I-mediated Ob-R activation. Downstream signaling molecules examined included JAK2, STAT3, Akt, and ERK1/2, all of which are functional in the leptin and IGF-IR pathways, as well as in multiple other signaling pathways. Thus, the IGF-I signaling experiments do not strictly indicate that IGF-I induces activation of one particular pathway. However, our results clearly indicate that IGF-I induces phosphorylation of Ob-R on Tyr<sup>1141</sup>. Phosphorylation of Tyr<sup>1141</sup> is required for Ob-R to bind to the STAT3 transcription factor, which is then activated by JAK2 and translocated to the nucleus to stimulate transcription of downstream target genes (26). Thus, our results indicate that IGF-I activates Ob-R via the IGF-IR kinase.

(c) Cross-talk is unidirectional, as leptin does not activate IGF-IR. Whereas it is feasible that other phosphorylation sites on IGF-IR may be affected by leptin stimulation, the three sites examined here (Tyr<sup>1131</sup> and Tyr<sup>1135/1136</sup>) were not affected by leptin. These three phosphorylation sites are the critical sites known to be required for IGF-IR mitogenicity and transforming activity (27). Thus, the inability of leptin to induce phosphorylation at these sites suggests that the leptin hormone alone is not likely to affect IGF-IR oncogenic function in breast cancer. However, because IGF-IR cross-talks to Ob-R, it is feasible that Ob-R may contribute to IGF-IR molecular or biological effects and is worthy of further study.

Thus, we have identified a novel receptor interaction and unidirectional cross-talk involving the IGF-IR and leptin receptor, which has not been previously described. Interestingly, Garofalo et al. (5) showed that IGF-I can induce leptin transcript levels in MCF7 cells. Our results further support this concept of IGF-I-mediated positive regulation of the leptin pathway.

Cross-talk from IGF-IR to other signaling pathways seems to be a potentially common mechanism used by cancer cells to enhance tumor growth and supports the significance of the IGF-I system to the biology of breast cancer, as well as the relevance of IGF-IR as a therapeutic target. We previously showed that IGF-IR cross-talks to the HER2 cell surface receptor in breast cancer cells that have become resistant to the HER2-targeted agent trastuzumab (19). Others have also shown that IGF-IR is capable of cross-signaling to the EGFR (18) and to the estrogen receptor (14). Thus, understanding the mechanisms by which IGF-IR mediates activation of other growth factor signaling pathways is important to breast cancer research. We have examined the role of the Src kinase family in mediating IGF-IR cross-talk to leptin receptor and have found that Src kinase inhibition does not inhibit IGF-IR/Ob-R cross-talk (not shown). Future studies will examine the molecular mechanisms mediating this receptor cross-talk. In addition, cotargeting leptin receptor and IGF-IR as a strategy to inhibit breast cancer progression, as well as the contribution of leptin receptor to IGF-I-mediated promitogenic and antiapoptotic effects, will be examined in breast cancer cells.

In summary, our results show, for the first time, that the IGF-I and leptin receptors physically form a protein complex in



**FIGURE 5.** Evidence of unidirectional cross-talk. Leptin does not induce phosphorylation of IGF-IR. MCF7 (**A**) and BT474 cells were serum-starved overnight and then stimulated with IGF-I (100 ng/mL) for 5 min or leptin (1,000 ng/mL) for 5 min or 0.5, 1, 3, or 6 h. Cells were lysed for protein, and total protein extracts (50  $\mu$ g) were immunoblotted (SS, serum-starved control) for p-Y<sup>1141</sup>-Ob-R, total Ob-R, p-Tyr<sup>1131</sup> IGF-IR, p-Tyr<sup>1135/1136</sup> IGF-IR, total IGF-IR  $\beta$ , and actin. Experiments were done at least twice. IGF-I stimulated phosphorylation of IGF-IR and Ob-R within 5 min in both cell lines as expected and served as a positive control. Leptin stimulated phosphorylation of Ob-R in both lines but did not induce phosphorylation of IGF-IR at the phosphorylation sites examined, suggesting that receptor cross-talk is unidirectional, occurring from IGF-I to Ob-R only.

breast cancer cell lines and, further, that there exists a one-way cross-talk whereby IGF-IR induces phosphorylation and activation of the leptin receptor in breast cancer.

## Materials and Methods

### Materials

Human recombinant IGF-I (Sigma) was dissolved at 100  $\mu$ g/mL in PBS and used at 100 ng/mL in culture. Human recombinant leptin (EMD Biosciences) was dissolved at 1 mg/mL in PBS and used at 100 or 1,000 ng/mL. I-OMe-AG538 IGF-IR kinase inhibitor (Sigma) was dissolved at 1 mmol/L in PBS and used at 10  $\mu$ mol/L in culture.

### Cell Culture

MDA-MB-231 (MDA231), MCF7, BT474, and SKBR3 breast cancer cells were purchased from the American Type Culture Collection and maintained in DMEM supplemented with 10% FCS.

### Ligand Stimulation


Cells were serum starved overnight, and then stimulated with IGF-I (100 ng/mL) for 1, 5, 15, 30, or 60 min or leptin (1,000 ng/mL) for 5 min, 0.5 h, 1 h, 3 h, or 6 h. In addition, a subset of cells were serum starved, treated with the IGF-IR kinase inhibitor I-OMe-AG538 (10  $\mu$ mol/L overnight), and stimulated with IGF-I (100 ng/mL).

### Immunoprecipitation

Total protein lysates (200  $\mu$ g) were incubated with 1  $\mu$ g of Ob-R or IGF-IR antibody or 1  $\mu$ g rabbit IgG, rotating for 4 h, followed by addition of protein A/G-agarose (Cell Signaling) and rotating overnight. Beads were then washed thrice in PBS containing 0.1% Tween 20 and immunoblotted to detect Ob-R (H-300, Santa Cruz), IGF-IR (polyclonal, Cell Signaling), EGFR (monoclonal 1F4, Cell Signaling), or insulin receptor  $\beta$  (polyclonal, Cell Signaling). Blots of immunoprecipitations were quantitated using NIH imaging software ImageJ.

### Immunoblotting

Cells were lysed in buffer containing 10 mmol/L Tris (pH 7.5), 100 mmol/L NaCl, 1 mmol/L EDTA, 1% NP40, and protease and phosphatase inhibitor cocktails (Sigma). Total protein extracts (50  $\mu$ g) were immunoblotted using the following antibodies at the indicated dilutions: IGF-IR $\beta$  (polyclonal at 1:1,000; Cell Signaling); p-Tyr<sup>1131</sup>-IGF-IR/ Tyr<sup>1146</sup>-IR (polyclonal at 1:200; Cell Signaling); p-Tyr<sup>1135/1136</sup>-IGF-IR/ Tyr<sup>1150/1151</sup>-IR (polyclonal at 1:200; Cell Signaling); leptin receptor (Ob-R; H-300 polyclonal at 1:200; Santa



**FIGURE 6.** A novel unidirectional cross-talk from IGF-IR to Ob-R in breast cancer. Our results indicate that the IGF-I and leptin receptors interact in human breast cancer cells. Furthermore, cross-talk occurs from IGF-IR to Ob-R, such that IGF-I stimulation induces phosphorylation and activation of Ob-R. IGF-IR kinase inhibition blocks IGF-I-mediated Ob-R activation. Cross-talk is unidirectional, as leptin does not activate IGF-IR.

Cruz Biotechnology); p-Y<sup>1141</sup>-Ob-R (polyclonal at 1:200; Santa Cruz); actin (monoclonal AC-15 at 1:5,000; Sigma Chemical); from Cell Signaling, polyclonal antibodies against p-STAT3 (Tyr<sup>705</sup>), total STAT3, p-JAK2 (Tyr<sup>221</sup>), total JAK2 (24B11), total Akt, p-Thr<sup>202</sup>/Tyr<sup>204</sup> p42/p44 MAPK (ERK1/2), total p42/p44 MAPK (ERK1/2), p-pThr<sup>180</sup>/Tyr<sup>182</sup> p38 MAPK, and total p38 MAPK, monoclonal 587F11 against p-Ser<sup>473</sup>-Akt, each used at 1:1,000 dilution, and monoclonal 1F4 anti-EGFR used at 1:200 dilution. Secondary antibodies were chosen according to the species of origin of the primary antibody. Protein bands were detected using the Odyssey Imaging System (Li-Cor Biosciences). Bands were quantitated using NIH imaging software ImageJ.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## References

- Reinier KS, Vacek PM, Geller BM. Risk factors for breast carcinoma *in situ* versus invasive breast cancer in a prospective study of pre- and post-menopausal women. *Breast Cancer Res Treat* 2007;103:343–48.
- Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. *J Clin Oncol* 2002;20:1128–43.
- Calle EE, Thun MJ. Obesity and cancer. *Oncogene* 2004;23:6365–78.
- Garofalo C, Surmacz E. Leptin and cancer. *J Cell Physiol* 2006;207:12–22.
- Garofalo C, Koda M, Cascio S, et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. *Clin Cancer Res* 2006;12:1447–53.
- Saxena NK, Sharma D, Ding X, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. *Cancer Res* 2007;67:2497–507.
- Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. *Eur J Endocrinol* 2000;143:293–311.
- Bahrenberg G, Behrmann I, Barthel A, et al. Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. *Mol Endocrinol* 2002;16:859–72.
- Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. *J Biol Chem* 1997;272:32686–95.
- Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. *Cancer Res* 2004;64:5870–5.
- Garofalo C, Sisci D, Surmacz E. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. *Clin Cancer Res* 2004;10:6466–75.
- Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. *Clin Cancer Res* 2004;10:4325–31.
- Cleary MP, Phillips FC, Getzin SC, et al. Genetically obese MMTV-TGF- $\alpha$ /Lep(ob)Lep(ob) female mice do not develop mammary tumors. *Breast Cancer Res Treat* 2003;77:205–15.
- Surmacz E. Function of the IGF-I receptor in breast cancer. *J Mammary Gland Biol Neoplasia* 2000;5:95–105.
- Kahan Z, Gardi J, Nyari T, et al. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study. *Int J Oncol* 2006;29:193–200.
- Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. *Oncogene* 2007;26:1636–44.
- Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. *Mol Cancer Ther* 2007;6:1–12.
- Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. *Endocrinology* 2005;146:4609–18.
- Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. *Cancer Res* 2005;65:11118–28.
- Novosyadlyy R, Dudas J, Pannem R, Ramadori G, Scharf JG. Crosstalk between PDGF and IGF-I receptors in rat liver myofibroblasts: implication for liver fibrogenesis. *Lab Invest* 2006;86:710–23.
- Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. *J Biol Chem* 2002;277:39684–95.
- Schaffler A, Scholmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. *Nat Clin Pract Endocrinol Metabol* 2007;3:345–54.
- Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. *Oncogene* 2000;19:889–98.
- Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). *Br J Cancer* 1995;72:1189–93.
- Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. *Cancer Res* 2003;63:4384–8.
- Cao Q, Mak KM, Lieber CS. Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. *J Hepatol* 2007;46:124–33.
- Li S, Ferber A, Miura M, Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. *J Biol Chem* 1994;269:32558–64.